$3.14
Theratechnologies
Performance
Dividends
57%
1W
1M
YTD
1Y
3Y
13/36
Growth Score
10/36
Dividend Score
Valuation
PE Ratio
-16.91
PS Ratio
1.71
RSI
-
3
PEG Ratio
0.01
2
PRG Ratio
0.59
PDG Ratio
0
Growth
02%05%0-4%015%
49%65%-156%877%
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule of 40
73.47%
3
Gross Margin
77.72%
0
Current Ratio
0.84
Return on Assets
-17.86%
Return on Equity
37.63%
Return on inv. Capital
60.74%
Institutional Holder
13.989.354012.914.189
34242
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 85.87M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -8.31M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 65.42M
2018
2019
2020
2021
2022
2023
2024
6
Events
THTX
Theratechnologies
in 254 days
before market open
Earnings per Share is expected with - and revenue with - .
THTX
Theratechnologies
in 212 days
before market open
Earnings per Share is expected with - and revenue with - .
THTX
Theratechnologies
in 74 days
before market open
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Drug Manufacturers - Specialty & Generic
IPO Date
13.02.2009
MaketCap
144.23M
Country
CA
CEO
Paul Lévesque
Description
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Updated 21.07.2025